An Irish company developing therapeutics for cancer has announced a research collaboration with Trinity College Dublin. The collaboration between Inflection Biosciences Ltd and the Trinity Biomedical Sciences Institute (TBSI) aims to explore the immunotherapeutic properties of one of the company’s products.
The emergence of immunotherapies, which harness the body’s own immune system to fight cancer, have been a significant advancement in cancer treatment over the past number of years. The collaboration has been supported by an Enterprise Ireland Innovation Voucher which facilitates research links between industry and Ireland’s Higher Education Institutes.
Speaking at the announcement of the collaboration, Trinity College’s Professor Ed Lavelle said: “I am excited about exploring the potential immunotherapeutic properties of Inflection Biosciences’ innovative dual mechanism inhibitors. Both PIM kinase and PI3K pathways are understood to play a role in regulating the body’s immune system and so inhibiting both should offer new promise. The initial data generated by the company already suggests an immunomodulatory profile and we look forward to better understanding the mechanism of that effect.”
Pictured above: Trinity College Dublin